Research Paper Volume 13, Issue 1 pp 241—261

In situ self-assembly of Au-antimiR-155 nanocomplexes mediates TLR3-dependent apoptosis in hepatocellular carcinoma cells

TLR3 is a direct target of miR-155. (A) qRT-PCR analysis of TLR3 expression in HCC tissues and ANCTs (n=30). (B) Western blot and densitometric quantification analysis of TLR3 expression in HCC tissues and ANCTs. (C) qRT-PCR analysis of TLR3 expression in HCC and normal liver cells (n=3). (D) TLR3 immunofluorescence in L02, HepG2 and SMMC-7721 cells. (E) RIP assay results showing co-precipitation of miR-155 and TLR3 by an Ago2 antibody in HepG2 cells. Verification of RIP products by qRT-PCR is also shown. (F) Schematic representation of the miR-155 binding site in the 3'-UTR region of TLR3 (WT, wild type; MUT, mutated type). (G) Luciferase activity assay results demonstrating direct targeting of the 3'UTR of TLR3 by miR-155 (n=3). **PP

Figure 4. TLR3 is a direct target of miR-155. (A) qRT-PCR analysis of TLR3 expression in HCC tissues and ANCTs (n=30). (B) Western blot and densitometric quantification analysis of TLR3 expression in HCC tissues and ANCTs. (C) qRT-PCR analysis of TLR3 expression in HCC and normal liver cells (n=3). (D) TLR3 immunofluorescence in L02, HepG2 and SMMC-7721 cells. (E) RIP assay results showing co-precipitation of miR-155 and TLR3 by an Ago2 antibody in HepG2 cells. Verification of RIP products by qRT-PCR is also shown. (F) Schematic representation of the miR-155 binding site in the 3'-UTR region of TLR3 (WT, wild type; MUT, mutated type). (G) Luciferase activity assay results demonstrating direct targeting of the 3'UTR of TLR3 by miR-155 (n=3). **P<0.01, *P < 0.05.